PROSTAR XL SUTURE-MEDIATED CLOSURE
Report
- Report Number
- 2024168-2013-00123
- Event Type
- Injury
- Date Received
- January 7, 2013
- Date of Event
- January 1, 2004
- Report Date
- December 12, 2012
- Manufacturer
- AV-TEMECULA-CT
- Product Code
- MGB
- PMA / PMN Number
- P960043
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- UK
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
(B)(4):DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION.(B)(4): CONCOMITANT MEDICAL PRODUCTS:GUIDE WIRE: STANDARD 0.035 GUIDEWIRE, AMPLATZ SUPER-STIFF WIRE.SHEATH: 9FR, 18 FR.OTHER: 21G MICROLANCE NEEDLE, MOSQUITO CLAMP, MEDTRONIC CORE VALVE SYSTEM. THE SAFETY AND EFFECTIVENESS OF THE PROSTAR XL DEVICE SYSTEM HAVE NOT BEEN ESTABLISHED IN PATIENTS WITH ANTEGRADE PUNCTURES.THE CUSTOMER REPORTED THE DEVICE WAS DISCARDED. THE LOT NUMBER WAS NOT IDENTIFIED. A FOLLOW-UP REPORT WILL BE SUBMITTED WITH ALL ADDITIONAL RELEVANT INFORMATION.LARGE CALIBRE ARTERIAL ACCESS DEVICE CLOSURE FOR PERCUTANEOUS AORTIC VALVE INTERVENTIONS: USE OF THE PROSTAR SYSTEM IN 118 CASES. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS 79:143-149, 2012. JAMES COCKBURN, MBBS, MD, MRCP, ADAM DE BELDER, MBBS, MD, MRCP, MICHAEL BROOKS, MBBS, FRCA, NEVIL HUTCHINSON, MBBS, FRCA, ANDREW HILL, MBBS, FRCA, UDAY TRIVEDI, MBBS, FRCS, AND DAVID HILDICK-SMITHMBBS, MD, FRCP. (B)(4).
(B)(4). IT IS INDICATED THAT THE DEVICE IS NOT RETURNING FOR EVALUATION; THEREFORE, A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. REVIEWS OF THE LOT HISTORY RECORD AND COMPLAINT HISTORY DATABASE COULD NOT BE CONDUCTED BECAUSE THE LOT NUMBER WAS NOT PROVIDED. BASED ON THE INFORMATION REVIEWED, THERE IS NO INDICATION OF A PRODUCT DEFICIENCY.
A PROSPECTIVE REVIEW OF PROCEDURAL DATA AND OUTCOMES COLLECTED FROM A DEDICATED DATABASE WAS PERFORMED IN 118 PATIENTS WHO UNDERWENT BALLOON AORTIC VALVULOPLASTY (BAV=54 PATIENTS/54 FEMORAL ARTERIES. FIFTY TWO WERE ANTEGRADE AND 2 WERE RETROGRADE PUNCTURES) AND TRANS-CATHETER AORTIC VALVE IMPLANTATION (TAVI=64. ALL ANTEGRADE PUNCTURES). THE PROSTAR XL DEVICE WAS USED USING THE PRECLOSE TECHNIQUE FOR VASCULAR CLOSURE. COMPLICATIONS IN THE TAVI GROUP WERE: MAJOR BLEEDING WAS SEEN IN 4.7% (3/64) OF CASES. DURING ONE OF THE MAJOR BLEEDING CASES, THE PATIENT ON INITIAL IMPLANTATION OF THE PROSTAR XL DEVICE INTO THE ARTERY THE INTRODUCER TOOK A SUBCUTANEOUS COURSE LEADING TO SIGNIFICANT ABDOMINAL TRACKING. THE DEVICE WAS SUCCESSFULLY RE-INTRODUCED INTO THE ARTERY. FOLLOWING THE TAVI, HEMOSTASIS WAS SUCCESSFULLY ACHIEVED WITH THE PROSTAR XL BUT BECAUSE OF THE ABDOMINAL DEVICE TRACKING, THE SURGEON CHOSE TO VISUALIZE THE ENTRY SITE DIRECTLY AND PLACE ADDITIONAL SUTURES. THREE HOURS POST PROCEDURE, THE PATIENT BECAME HYPOTENSIVE WITH SOME LOIN PAIN. THE PATIENT WAS TAKEN BACK TO CATHETER LABORATORY AND AN ANGIOGRAM CONFIRMED A SMALL ONGOING LEAK AT THE ENTRY POINT OF THE COMMON FEMORAL ARTERY. AN OCCLUSION BALLOON WAS INTRODUCED FROM THE CONTRALATERAL FEMORAL ARTERY AND GENTLY INFLATED TO LOW PRESSURE FOR 30 MIN, WITH DEFLATION FOR 30 SECONDS EVERY 5 MINUTES TO ALLOW LIMB PERFUSION. THIS SUCCESSFULLY ALLOWED THE LEAK TO SEAL. INTRAVENOUS GLYCERYL TRINITRATE INFUSION TO KEEP THE SYSTOLIC BLOOD PRESSURE BELOW 120 MM HG WAS USED FOR 12 HOURS AND THERE WERE NO FURTHER COMPLICATIONS. THE PHYSICIANS ARE REPORTED TO BE TRAINED IN THE USE OF THE PROSTAR XL DEVICE. NO ADDITIONAL INFORMATION WAS PROVIDED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 6246 | PROSTAR XL SUTURE-MEDIATED CLOSURE | SUTURE MEDIATED CLOSURE | MGB | AV-TEMECULA-CT |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 80 YR | Required Intervention | CONCOMITANT MEDICAL DEVICES |